BRANSON, Mo. - TelAve -- Following the scheduled filing of foundational intellectual property for its Smart LNP 3.0 platform a novel biodegradable ionizable lipid polysarcosine conjugate Metavalis is moving to appoint four strategic partners to guide the asset through pre clinical validation and FDA Pre IND pathways.

​"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."

​Open Advisory Seats:

Metavalis is currently accepting inquiries for the following strategic roles:

​The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.

​The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).

More on TelAve News

• Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
• David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
• "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
• Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
• U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis

​The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.

​The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.

​About Metavalis Inc.

Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.

​Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.

You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/

​Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.